Novartis AG Peer Comparison

Metric Value Ranking
Market Cap $224.0 Billion 6/11 LLY
$846.9B		 JNJ
$388.0B		 ABBV
$327.9B		 MRK
$286.5B		 AZN
$246.7B		 NVS
$224.0B		 PFE
$162.1B		 SNY
$141.0B		 BMY
$109.0B		 GILD
$105.5B		 GSK
$80.5B
Gross Margin 74% 6/11 MRK
81%		 LLY
81%		 JNJ
79%		 GILD
78%		 AZN
76%		 NVS
74%		 GSK
74%		 SNY
68%		 ABBV
67%		 PFE
62%		 BMY
56%
Profit Margin 26% 2/11 MRK
30%		 NVS
26%		 LLY
26%		 GILD
23%		 JNJ
21%		 GSK
15%		 AZN
15%		 BMY
14%		 ABBV
11%		 SNY
11%		 PFE
0%
EBITDA margin 41% 4/11 GILD
49%		 BMY
42%		 LLY
42%		 NVS
41%		 ABBV
41%		 MRK
41%		 GSK
33%		 AZN
32%		 JNJ
29%		 PFE
27%		 SNY
26%
Quarterly Revenue $12.5 Billion 6/11 SNY
$23.3B		 JNJ
$22.4B		 MRK
$15.8B		 PFE
$13.3B		 AZN
$12.9B		 NVS
$12.5B		 ABBV
$12.3B		 BMY
$12.2B		 LLY
$11.3B		 GSK
$10.1B		 GILD
$6.9B
Quarterly Earnings $3.2 Billion 3/11 MRK
$4.8B 		JNJ
$4.7B 		NVS
$3.2B 		LLY
$3.0B 		SNY
$2.5B 		AZN
$1.9B 		BMY
$1.7B 		GILD
$1.6B 		GSK
$1.5B 		ABBV
$1.4B 		PFE
$24.0M
Quarterly Free Cash Flow $4.1 Billion 2/11 JNJ
$4.7B 		NVS
$4.1B 		ABBV
$3.8B 		AZN
$2.5B 		MRK
$2.2B 		BMY
$2.1B 		GILD
$1.2B 		GSK
$564.1M 		LLY
$63.4M 		SNY
-$553.8M 		PFE
-$2.4B
Trailing 4 Quarters Revenue $48.2 Billion 7/11 JNJ
$86.6B		 SNY
$74.6B		 MRK
$61.4B		 PFE
$55.6B		 ABBV
$54.4B		 AZN
$49.1B		 NVS
$48.2B		 BMY
$46.5B		 GSK
$40.3B		 LLY
$38.9B		 GILD
$27.8B
Trailing 4 Quarters Earnings $16.2 Billion 2/11 SNY
$23.3B 		JNJ
$22.4B 		MRK
$15.8B 		PFE
$13.3B 		AZN
$12.9B 		NVS
$12.5B 		ABBV
$12.3B 		BMY
$12.2B 		LLY
$11.3B 		GSK
$10.1B 		GILD
$6.9B
Quarterly Earnings Growth 40% 6/11 ABBV
473% 		MRK
69% 		LLY
68% 		SNY
57% 		GILD
54% 		NVS
40% 		AZN
6% 		JNJ
-9% 		BMY
-19% 		GSK
-28% 		PFE
-99%
Annual Earnings Growth 76% 2/11 JNJ
670% 		NVS
76% 		LLY
27% 		SNY
6% 		AZN
-11% 		ABBV
-22% 		GSK
-34% 		GILD
-74% 		MRK
-81% 		PFE
-114% 		BMY
-174%
Quarterly Revenue Growth -10% 10/11 SNY
99% 		AZN
13% 		GSK
10% 		BMY
9% 		MRK
9% 		GILD
5% 		PFE
4% 		ABBV
1% 		LLY
0% 		NVS
-10% 		JNJ
-12%
Annual Revenue Growth -10% 9/11 LLY
86% 		SNY
57% 		GSK
12% 		AZN
12% 		MRK
10% 		GILD
8% 		BMY
3% 		ABBV
-6% 		NVS
-10% 		JNJ
-13% 		PFE
-18%
Cash On Hand $7.9 Billion 3/11 JNJ
$24.9B 		ABBV
$18.1B 		NVS
$7.9B 		SNY
$7.5B 		AZN
$6.9B 		BMY
$6.3B 		MRK
$5.7B 		GSK
$3.8B 		LLY
$3.2B 		GILD
$2.8B 		PFE
$1.1B
Short Term Debt $7.8 Billion 5/11 PFE
$11.9B 		SNY
$10.5B 		ABBV
$10.2B 		JNJ
$9.9B 		NVS
$7.8B 		AZN
$5.4B 		LLY
$5.2B 		GSK
$4.3B 		BMY
$3.7B 		MRK
$3.1B 		GILD
$1.8B
Long Term Debt $19.7 Billion 9/11 ABBV
$63.8B		 PFE
$57.5B		 BMY
$48.9B		 JNJ
$31.6B		 MRK
$31.1B		 AZN
$27.2B		 LLY
$23.7B		 GILD
$21.5B		 NVS
$19.7B		 GSK
$17.4B		 SNY
$13.7B
PE 13.85 8/11 MRK
124.26		 LLY
115.35		 GILD
100.19		 ABBV
54.72		 AZN
38.31		 SNY
16.30		 GSK
15.56		 NVS
13.85		 JNJ
10.21		 PFE
-1.00		 BMY
-1.00
PS 4.65 5/11 LLY
21.76		 ABBV
6.03		 AZN
5.02		 MRK
4.67		 NVS
4.65		 JNJ
4.48		 GILD
3.79		 PFE
2.91		 BMY
2.34		 SNY
1.72		 GSK
1.56
PB 5.34 8/11 LLY
62.11		 ABBV
40.75		 MRK
7.09		 BMY
6.39		 AZN
6.23		 GILD
5.80		 JNJ
5.42		 NVS
5.34		 GSK
4.56		 PFE
1.84		 SNY
1.76
PC 28.34 6/11 LLY
262.72		 PFE
154.11		 MRK
50.53		 GILD
38.06		 AZN
35.68		 NVS
28.34		 GSK
21.19		 SNY
18.88		 ABBV
18.15		 BMY
17.31		 JNJ
15.60
Liabilities to Equity 1.33 10/11 ABBV
17.59		 BMY
4.56		 LLY
4.29		 GSK
3.08		 GILD
1.94		 AZN
1.64		 MRK
1.62		 JNJ
1.53		 PFE
1.46		 NVS
1.33		 SNY
0.78
ROA 0.17 2/11 JNJ
21% 		NVS
17% 		LLY
10% 		GSK
9% 		SNY
7% 		AZN
6% 		ABBV
4% 		GILD
2% 		MRK
2% 		PFE
-1% 		BMY
-7%
ROE 0.39 4/11 ABBV
75% 		LLY
54% 		JNJ
53% 		NVS
39% 		GSK
36% 		AZN
16% 		SNY
12% 		GILD
6% 		MRK
6% 		PFE
-3% 		BMY
-38%
Current Ratio 1.75 2/11 SNY
2.29		 NVS
1.75		 PFE
1.69		 JNJ
1.65		 MRK
1.62		 AZN
1.61		 GILD
1.51		 GSK
1.31		 LLY
1.23		 BMY
1.22		 ABBV
1.06
Quick Ratio 0.15 2/11 MRK
124.26		 LLY
115.35		 GILD
100.19		 ABBV
54.72		 AZN
38.31		 SNY
16.30		 GSK
15.56		 NVS
13.85		 JNJ
10.21		 PFE
-1.00		 BMY
-1.00
Long Term Debt to Equity 0.47 9/11 ABBV}
7.97		 BMY}
2.87		 LLY}
1.75		 GILD}
1.18		 GSK}
0.94		 MRK}
0.77		 AZN}
0.69		 PFE}
0.66		 NVS}
0.47		 JNJ}
0.44		 SNY}
0.17
Debt to Equity 0.69 9/11 ABBV
9.24		 BMY
3.17		 LLY
2.13		 GILD
1.28		 GSK
1.18		 MRK
0.85		 AZN
0.85		 PFE
0.79		 NVS
0.69		 JNJ
0.58		 SNY
0.33
Burn Rate -15.24 9/11 SNY
16.54		 AZN
13.78		 BMY
5.24		 ABBV
4.84		 PFE
0.20		 MRK
-2.06		 LLY
-4.43		 GILD
-9.24		 NVS
-15.24		 GSK
-24.84		 JNJ
-26.00
Cash to Cap 0.04 6/11 BMY
0.06		 ABBV
0.06		 JNJ
0.06		 GSK
0.05		 SNY
0.05		 NVS
0.04		 GILD
0.03		 AZN
0.03		 MRK
0.02		 PFE
0.01		 LLY
0.00
CCR 1.28 3/11 ABBV
2.81		 AZN
1.31		 NVS
1.28		 BMY
1.23		 JNJ
0.99		 GILD
0.74		 MRK
0.47		 GSK
0.38		 LLY
0.02		 SNY
-0.22		 PFE
-100.79
EV to EBITDA 48.14 7/11 LLY}
184.92		 ABBV}
75.82		 AZN}
66.37		 PFE}
63.86		 JNJ}
62.66		 MRK}
48.60		 NVS}
48.14		 GSK}
44.64		 GILD}
37.28		 SNY}
31.64		 BMY}
30.46
EV to Revenue 5.08 5/11 LLY
22.42		 ABBV
7.06		 AZN
5.56		 MRK
5.13		 NVS
5.08		 JNJ
4.67		 GILD
4.54		 PFE
4.14		 BMY
3.37		 GSK
2.91		 SNY
2.30

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions